INO has been in the news 357% more than usual
Mar 04, 2026, 3:31 PM
0.29%
What does INO do
Inovio Pharmaceuticals, based in San Diego, develops DNA medicines targeting infectious diseases, cancer, and HPV-related conditions, with key candidates including INO-3107 for recurrent respiratory papillomatosis. The company employs 122 people and utilizes CELLECTRA devices for DNA delivery.
INO has been in the news recently: Investors in Inovio Pharmaceuticals, Inc. who experienced losses from October 10, 2023, to December 26, 2025, can join a class action lawsuit for alleged securities fraud with a deadline of April 7, 2026. Additionally, Inovio Pharmaceuticals is collaborating with Akeso, Inc. to initiate a Phase 2 trial of INO-5412 combined with cadonilimab as a potential treatment for glioblastoma in late 2026.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.